{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:22Z","timestamp":1761901642712,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"am","delay-in-days":304,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-COHO-002"],"award-info":[{"award-number":["ANR-10-COHO-002"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102470","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T11:39:18Z","timestamp":1598528358000},"page":"102470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["High effector-memory CD8+ T-cell levels correlate with high PML risk in natalizumab-treated patients"],"prefix":"10.1016","volume":"46","author":[{"given":"Asma","family":"Beldi-Ferchiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abir","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Duchmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Hodel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivania","family":"Patry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Delfau-Larue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Molinier-Frenkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Cr\u00e9ange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102470_bib0001","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.msard.2020.102470_bib0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.msard.2020.102470_bib0003","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/14737175.4.4.571","article-title":"Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS","volume":"4","author":"Rudick","year":"2004","journal-title":"Expert review of neurotherapeutics"},{"key":"10.1016\/j.msard.2020.102470_bib0004","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrd1752","article-title":"Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab","volume":"4","author":"Steinman","year":"2005","journal-title":"Nature reviews Drug discovery"},{"key":"10.1016\/j.msard.2020.102470_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annual review of medicine"},{"key":"10.1016\/j.msard.2020.102470_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","article-title":"Classifying PML risk with disease modifying therapies","volume":"12","author":"Berger","year":"2017","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1016\/j.msard.2020.102470_bib0007","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"Sorensen","year":"2012","journal-title":"Multiple sclerosis"},{"key":"10.1016\/j.msard.2020.102470_bib0008","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Annals of neurology"},{"key":"10.1016\/j.msard.2020.102470_bib0009","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.msard.2020.102470_bib0010","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","article-title":"Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification","volume":"88","author":"Schwab","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102470_bib0011","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2020.102470_bib0012","article-title":"Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France","author":"Vukusic","year":"2019","journal-title":"JAMA neurology"},{"key":"10.1016\/j.msard.2020.102470_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160277","article-title":"Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: implications for JCV Reactivation","volume":"11","author":"Iannetta","year":"2016","journal-title":"PloS one"},{"key":"10.1016\/j.msard.2020.102470_bib0014","first-page":"837","volume":"20","author":"Jilek","year":"2014"},{"key":"10.1016\/j.msard.2020.102470_bib0015","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/eji.201142108","article-title":"Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis","volume":"42","author":"Planas","year":"2012","journal-title":"European journal of immunology"},{"key":"10.1016\/j.msard.2020.102470_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5297980","article-title":"JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus","volume":"2018","author":"Zingaropoli","year":"2018","journal-title":"BioMed research international"},{"key":"10.1016\/j.msard.2020.102470_bib0017","first-page":"668","article-title":"Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab","volume":"5","author":"Antoniol","year":"2014","journal-title":"Frontiers in immunology"},{"key":"10.1016\/j.msard.2020.102470_bib0018","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102470_bib0019","first-page":"1048","volume":"22","author":"Schwab","year":"2016"},{"key":"10.1016\/j.msard.2020.102470_bib0020","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1212\/WNL.0000000000003401","article-title":"CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy","volume":"87","author":"Pignolet","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102470_bib0021","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1212\/WNL.0000000000008135","article-title":"Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals","volume":"93","author":"Schwab","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102470_bib0022","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12974-015-0365-x","article-title":"Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells","volume":"12","author":"Spadaro","year":"2015","journal-title":"Journal of neuroinflammation"},{"key":"10.1016\/j.msard.2020.102470_bib0023","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the Human Immunology Project","volume":"12","author":"Maecker","year":"2012","journal-title":"Nature reviews Immunology"},{"key":"10.1016\/j.msard.2020.102470_bib0024","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.0000000000002314","article-title":"CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients","volume":"86","author":"Lieberman","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102470_bib0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1352458511421919","article-title":"Immunological and clinical consequences of treating a patient with natalizumab","volume":"18","author":"Schwab","year":"2012","journal-title":"Multiple sclerosis"},{"key":"10.1016\/j.msard.2020.102470_bib0026","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.22107","article-title":"Assessment of JC virus DNA in blood and urine from natalizumab-treated patients","volume":"68","author":"Rudick","year":"2010","journal-title":"Annals of neurology"},{"key":"10.1016\/j.msard.2020.102470_bib0027","doi-asserted-by":"crossref","first-page":"11918","DOI":"10.1128\/JVI.77.22.11918-11926.2003","article-title":"Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy","volume":"77","author":"Du Pasquier","year":"2003","journal-title":"Journal of virology"},{"key":"10.1016\/j.msard.2020.102470_bib0028","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/brain\/awh215","article-title":"A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy","volume":"127","author":"Du Pasquier","year":"2004","journal-title":"Brain: a journal of neurology"},{"key":"10.1016\/j.msard.2020.102470_bib0029","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneuroim.2006.04.003","article-title":"JC virus induces a vigorous CD8+ cytotoxic T cell response in multiple sclerosis patients","volume":"176","author":"Du Pasquier","year":"2006","journal-title":"Journal of neuroimmunology"},{"key":"10.1016\/j.msard.2020.102470_bib0030","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1128\/JVI.00131-13","article-title":"Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy","volume":"87","author":"Hendel-Chavez","year":"2013","journal-title":"Journal of virology"},{"key":"10.1016\/j.msard.2020.102470_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007365","article-title":"CD4 T cells control development and maintenance of brain-resident CD8 T cells during polyomavirus infection","volume":"14","author":"Mockus","year":"2018","journal-title":"PLoS pathogens"},{"key":"10.1016\/j.msard.2020.102470_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003014","article-title":"Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Perkins","year":"2012","journal-title":"PLoS pathogens"},{"key":"10.1016\/j.msard.2020.102470_bib0033","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1084\/jem.20140540","article-title":"VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells","volume":"211","author":"Schneider-Hohendorf","year":"2014","journal-title":"The Journal of experimental medicine"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:23Z","timestamp":1761900743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820305459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":33,"alternative-id":["S2211034820305459"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102470","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High effector-memory CD8+ T-cell levels correlate with high PML risk in natalizumab-treated patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102470"}}